Good day, and thank you for standing by. Welcome to the Keenova's fourth quarter 2025 earnings announcement conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Gerard Meuchner. Sir, please go ahead. Thank you, operator, and welcome everyone. Before we begin, let me remind you that we will make forward-looking statements on this call and actual results may differ materially from those expressed or implied in these statements. These statements are made as of today, March 31 2026, and we undertake no obligation to update them except as required by law. Please refer to our SEC filings for a detailed discussion of the risks and uncertainties affecting our business. We will also reference certain non-GAAP financial measures on this call. Reconciliations to the most directly comparable GAAP measures are included in our earnings release and in the investor presentation available on the investor relations section of our website at keenova.com. We use our website as a channel to distribute important and time-critical company information, and you should look to the investor relations page of the website for this information. Additionally, as we disclosed in a Form 8-K earlier this morning, because the company requires additional time to complete our 2025 Form 10-K as a result of the complexity of the accounting related to the business combination and the spin-off, we will file for an automatic 15 day extension. As such, we intend to file the Form 10-K by April 15. Please see our Form 8-K for further details. As noted in our earnings release on July 31 2025, the company completed its merger with Endo, and on November 10 2025, it completed the separation of Par Health. The unaudited 2025 financial results presented on today's call and in our presentation reflect Keenova's continuing operations. Such financial results are subject to completion of the company's financial closing procedures. Actual results may differ materially from these unaudited financial results. 2024 results presented today were prepared on a pro forma basis as if the merger and separation had each occurred at the beginning of the respective periods presented. Pro forma combined results for 2024 also exclude the results of the company's former Therakos business, which was sold in 2024. Pro forma combined results for 2025, excuse me, for 2024 and 2025 also exclude Endo's International Pharmaceuticals business, which was sold in 2025. Joining me on today's call are Siggi Olafsson, our President and Chief Executive Officer, and Christiana Stamoulis, our President and Chief Financial Officer. I'll now turn the call over to Siggi. Thanks, Gerard, and good morning, everyone. 2025 was a defining year for Keenova, and I'm incredibly proud of what the team has accomplished. We completed the merger of Mallinckrodt and Endo in July, successfully separated Par Health in November, and launched Keenova as a branded therapeutics company focused on area of high unmet need. Looking ahead, we are preparing to pursue a listing of Keenova's ordinary shares on the New York Stock Exchange in the second half of 2026, subject to board approval and other customary conditions. Throughout this period of transformation, our teams have maintained strong execution, and our results reflect that focus. We delivered fourth quarter performance ahead of our expectations, closing the year with a double-digit top-line growth and meaningful adjusted EBITDA expansion in the quarter. For the full year, we generated $1.93 billion of net sales and $609 million in adjusted EBITDA, reflecting a continued momentum across our core franchises, partly offset by the impact of merger-related compensation costs. We also realized $13 million in pre-tax synergies in fourth quarter of 2025 and remain on track to achieve $150 million of annual pre-tax run rate synergies by the third anniversary of Acthar Gel was once again a standout, delivering its second consecutive year of double-digit growth with 39% full-year net sales growth. XIAFLEX grew mid-single digits for both quarters and full year, and INOmax demonstrated resilience globally despite U.S. competitive pressures. Consistent with our focus on investing in organic growth, we are pleased to report clinical trial progress for XIAFLEX in additional indications. With that context, let me turn to our portfolio performance. Turning to slide six, since we officially launched Keenova only a few months ago, I'll spend a moment talking about who we are. Underpinned by our rare disease capabilities, Keenova develops, manufactures, and commercialize a portfolio of branded pharmaceutical products addressing specialty therapeutics areas of significant unmet need. This includes rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. The name Keenova reflects two complementary attributes of our company. A keen focus on helping patients receive the care they deserve, and the innovation required to develop our therapeutics. Our tagline, "Keen to solve, keen to serve," underscores our commitment to solving the challenges our patients face and serving them with integrity. Our diversified portfolio is anchored by Acthar Gel and XIAFLEX, which were the key drivers behind our growth in 2025. We are excited to be moving forward as a new company with a new identity and the strong foundation we have in place position us well for 2026 and beyond. Let's zero in on our pipelines for XIAFLEX on slide seven, where we continue to execute against our product development roadmap to expand the addressable market of the franchise and reinforce its long-term growth profile. We were very pleased to report in today's press release that our proof of concept study evaluating XIAFLEX for hammertoe met its primary safety endpoint and secondary exploratory efficacy endpoints with top-line data demonstrating a favorable s. This achievement enables us to progress the program into phase III study, which we expect to start in fourth quarter 2026. This is a great example of our growth strategy in action, and we see a meaningful opportunity to provide critical treatment for patients diagnosed with this condition, which is one of the most common deformities of the forefoot, according to the National Library of Medicine. We also advanced our clinical program for XIAFLEX in plantar fibromatosis. Patient enrollment for the phase III study was completed on March 5th. Top-line results from the study are expected in the third quarter of 2026, and we are targeting a regulatory submission in the fourth quarter of 2026. Separately, on the pipeline, we were pleased to receive approval in Japan for both medical device and drug application for INOmax Evolve this year. Turning to slide eight, before Christiana discusses our financial results in detail, I'd like to touch on our balance sheet and capital allocation priorities. We exited 2025 with a strong and flexible balance sheet that supports the continued investment in driving sustainable growth. At year-end, we had approximately $813 million of cash and cash equivalents and $2.481 billion of total debt outstanding, representing a net debt to covenant adjusted EBITDA ratio of approximately 1.98x. As we look toward 2026, our capital allocation priorities are clear. We will invest in organic growth to support Acthar Gel and XIAFLEX and fund targeted R&D to enhance the durability of our portfolio. We will also evaluate value-enhancing portfolio opportunities, exploring bolt-on acquisitions that leverage our existing capabilities to add to growth, as well as opportunistic divestitures, including a potential sale of our PERCOCET business. We believe the combination of established commercial franchises and targeted pipeline expansion provides a clear path of sustainable revenue growth and market, and margin expansion over time. All of our capital deployment decision will be made in accordance with a rigorous return framework, prioritizing opportunities that enhance cash flow generation, support durable growth, and create a long-term shareholder value. Thanks to the focus and hard work of our teams, our recent results demonstrate the momentum we are building across the business as we move into 2026. With that, I'll turn the call over to Christiana. Thank you, Siggi, and good morning, everyone. Before reviewing our results, I wanted to reiterate that the 2025 financial results presented on this call and in our presentation reflect Keenova's continuing operations, and the 2024 results were prepared on a pro forma combined historical basis to facilitate a consistent year-over-year comparison. Moving to our fourth quarter 2025 financial results on slide nine. Net sales were $542 million in the fourth quarter, including approximately $10 million in license revenue for a Novavax sales milestone. This reflects an increase of 17% compared to the prior year period, driven by Acthar Gel and growth in XIAFLEX. Adjusted EBITDA was $215 million, primarily driven by the Acthar Gel and XIAFLEX net sales and the realization of initial synergies in Q4. Now turning to our full year results on slide 10. Net sales for 2025 were $1.93 billion, an increase of 11% compared to 2024, driven by the growth in Acthar and XIAFLEX. Adjusted EBITDA was $609 million, excluding transaction-related compensation expenses of approximately $123 million and including the annualized impact of costs transferred to Par Health and synergies realized in Q4. Adjusted EBITDA from continuing operations was $732 million, representing a 17% increase compared to 2024, primarily driven by the strength of our core franchises and the impact of realized synergies. Let's now take a look at the key drivers of our performance, starting with Acthar Gel. Net Acthar Gel in the fourth quarter of 2025 were $206 million, representing an increase of 48% compared to net sales of $139 million in the fourth quarter of 2024. Full year net sales for 2025 were $677 million, representing an increase of 39% compared to net sales of $486 million in 2024. This marks the eighth consecutive quarter of Acthar Gel and the second straight year of double-digit growth. We are seeing robust patient Acthar Gel and continued momentum in uptake of our innovative SelfJect device as a result of our commercial investments and strong execution, which have driven greater category awareness and expansion. Acthar Gel growth in 2025 reflected a significant benefit from improved patient access. While we expect improved access to continue supporting patient demand in 2026, its Acthar Gel's growth rate is expected to moderate. Turning to XIAFLEX. Net sales for XIAFLEX in the fourth quarter of 2025 were $157 million, an increase of 6% compared to net sales of $148 million in the fourth quarter of 2024 when the product was owned by Endo. Full year net sales for 2025 were $546 million, an increase of 6% compared to net sales of $516 million in 2024. Growth was driven by increased pricing and demand stemming from Peyronie's disease. Turning now to an update on our merger-related synergies. As Siggi mentioned, we realized $13 million in pre-tax synergies in the fourth quarter of 2025, and we remain on track to deliver the full synergy plan. For the full year 2026, we expect to realize approximately $100 million in pre-tax synergies, and by the end of July 2028, three years post-merger, we expect to achieve $150 million in annual pre-tax run rate synergies. Lastly, let's turn to guidance. For the full year 2026, we expect net Acthar Gel to grow in the mid-teens%, net sales for XIAFLEX to grow in the mid- to high-single digits%, total net sales of $1.94 billion-$2 billion and adjusted EBITDA of $730 million-$760 million, which includes the anticipated 2026 merger synergies. We Acthar Gel patient demand will again be driven by SelfJect uptake and category awareness expansion, and we expect XIAFLEX demand to be driven by heightened patient awareness. Finally, as a result of typical first quarter dynamics and the adverse weather we experienced earlier in the quarter, we expect net Acthar Gel and XIAFLEX in the first quarter of 2026 to be the lowest relative to the prior and subsequent quarters. I'll now hand over the call back to Siggi for closing remarks. Thank you, Christiana. Our achievements in 2025 give me deep confidence in Keenova's bright future. As we conclude today's call, I want to express my gratitude to our team and their commitment to serving our patient needs. Their efforts are making our mission a reality, and we see great opportunities ahead for Keenova in 2026. We will now open the call for Q&A. Thank you. As a reminder to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. One moment while we compile our Q&A roster. It looks like our first question is gonna come from the line of Matthew Russell with Hudson Bay. Your line is open. Please go ahead. Hey, Siggi and Christiana. I just had a question about the EBITDA guidance. I think on slide 10, the pro forma EBITDA was $732 million. If we're bridging from $13 million synergies to $100 million realized in 2026, and if Acthar revenue is growing by $100 million and XIAFLEX by $40 million, doesn't that imply something like $900 million of EBITDA? What's the delta there? Hi, this is Christiana. Thank you for your question. The number that you are seeing for 2025 reflects annualized synergies from the costs that were transferred to Par Health. In addition to the $13 million actual synergies, you see also the impact of full annualized synergies in the 2025 number. That's why when we compare 2026 to 2025, you see less of growth because 2025 has been pro forma for the annualized synergies. So- [crosstalk] The actual synergies. 2025 has $100 million. Does 2025 have $100 million add back for synergies? The 25 total has $68 million in synergies. Okay. On an annualized basis. Okay. Is there anything offsetting? You'll still see an uplift from synergies year-over-year, I guess, instead of, you know, 68 going to 100. What about those deltas on revenue on your big two line items? Are they not flowing through to the bottom line? They do. The impact that you see from the growth in revenues is partially offset by increased investment in supporting the growth of Acthar and also preparing for potential additional indications for XIAFLEX. This is what you see as an increasing cost offsetting the benefit of the incremental synergies. Okay. Thank you. Thanks a lot. Thank you. I would now like to hand the conference back over to Gerard Meuchner for closing remarks. Thank you, operator, and thanks Siggi and Christiana, and thank you all for joining us today. We look forward to engaging with you in the days and weeks ahead. If you have any questions, the best way to contact us would be via email, and we will work to get back to you as soon as possible. Thank you. This concludes today's conference call. Thank you for participating, and you may now disconnect. Everyone, have a great day.